PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial
Written by Ι Stock Market Media — December 12, 2016
All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company’s clinical trial, PharmaCyte qualified to use its multi-million dollar “at-the-market” funding arrangement with Chardan Capital in order to enroll every single patient into its ...
Read More →
12
DEC
Share
PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principle Investigator
LAGUNA HILLS, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the first article in a series of Q&A articles that will be conducted with some of the key team members of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s first Q&A article is with Dr. Matthias Löhr of the famed ...
Read More →
7
DEC
Share
PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial
SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...
Read More →
6
JAN
Share
PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study
Written by Ι Stock Market Media — June 3, 2015
NEW YORK, NY — PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.
It was a study ...
Read More →
3
JUN
Share
PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials
Written by Ι Stock Market Media Group — April 23, 2015
PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce ...
Read More →
23
APR
Share
Nuvilex Announces Name Change to PharmaCyte Biotech
SILVER SPRING, MD., Jan. 7, 2015 — Nuvilex, Inc. (NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change ...
Read More →
7
JAN
Share
